Indications
Therapeutic Asset Ratings
9,922 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
LY3143921
Non-Small Cell Squamous Lung Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Esophageal Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Head And Neck Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Urothelial Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Triple-Negative Breast Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Malignant Pancreatic Neoplasm
Cancer Research UK
P1
CC
(43)
LY 3410738
Cancer
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Chondrosarcoma
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Chronic Myelomonocytic Leukemia
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Myelodysplastic Syndrome
Eli Lilly and Company
P1
CC
(43)
ly3885125
Inherited Lipid Metabolism Disorder
Eli Lilly and Company
P1
CC
(43)
ly4050784
SMARCA4-Deficient Sarcoma Of Thorax
Eli Lilly and Company
P1
CC
(43)
ly4052031
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4052031
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4052031
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4101174
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4101174
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4101174
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Marginal Zone Lymphoma
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Follicular Lymphoma
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Mantle Cell Lymphoma
Eli Lilly and Company
P1
CC
(43)
ly4170156
Triple-Negative Breast Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4257496
Esophageal Cancer
Eli Lilly and Company
P1
CC
(43)
ly4257496
Prostate Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4337713
Esophageal Cancer
Eli Lilly and Company
P1
CC
(43)
Showing 2726 to 2750 of 9,922 assets
Previous
Page 110 of 397
Next
